(Q34119629)

31 July 2017

1 reference

title

Marine organisms as a source of new anticancer agents (English)

1 reference

31 July 2017

1 reference

G Schwartsmann

1

1 reference

31 July 2017

A Brondani da Rocha

series ordinal

2

1 reference

31 July 2017

R G Berlinck

series ordinal

3

1 reference

31 July 2017

J Jimeno

series ordinal

4

1 reference

31 July 2017

publication date

1 April 2001

1 reference

Lancet Oncology Commission

31 July 2017

published in

1 reference

31 July 2017

volume

2

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

221-225

1 reference

Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Natural products in drug discovery and development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Anticancer drug screening and discovery in the 1990s: a European perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Marine organisms and other novel natural sources of new cancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Discovery and development of antineoplastic agents from natural sources

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Summary of the Workshop on Drug Development, Biological Diversity, and Economic Growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Antitumor compounds from tunicates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Isolation and structure of bryostatin 1

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

A phase II study of bryostatin 1 in metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Cyclic peptides and depsipeptides from cyanobacteria: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Granulatimide and Isogranulatimide, Aromatic Alkaloids with G2 Checkpoint Inhibition Activity Isolated from the Brazilian AscidianDidemnumgranulatum: Structure Elucidation and Synthesis†

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

New bisindole alkaloids of the topsentin and hamacanthin classes from the Mediterranean marine sponge Rhaphisia lacazei

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Bioactive sesquiterpenes from a Taiwanese marine sponge Parahigginsia sp

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Makaluvamines vary in ability to induce dose-dependent DNA cleavage via topoisomerase II interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Polyketides from dinoflagellates: origins, pharmacology and biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Rational design of aromatic polyketide natural products by recombinant assembly of enzymatic subunits

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Kahalalide K: A new cyclic depsipeptide from the hawaiian green alga bryopsis species

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

Antitumor activity of cryptophycins: effect of infusion time and combination studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900292-8

7 January 2021

10.1016/S1470-2045(00)00292-8

Identifiers

DOI

1 reference

31 July 2017

1 reference